Health and Fitness Health and Fitness
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ] - Market Wire
00 p.m. EDT
Wed, May 2, 2012
[ Wed, May 02nd 2012 ] - Market Wire
Location Change
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012
Tue, April 24, 2012

Mylan Launches First Generic Version of Doryx 150 mg


//health-fitness.news-articles.net/content/2012/ .. nches-first-generic-version-of-doryx-150-mg.html
Published in Health and Fitness on Monday, April 30th 2012 at 11:32 GMT by Market Wire   Print publication without navigation


Mylan Launches First Generic Version of Doryx 150 mg -- PITTSBURGH, April 30, 2012 /PRNewswire/ --

Mylan Launches First Generic Version of Doryx 150 mg

[ ]

Court Rules in Favor of Mylan in Warner Chilcott's Patent Infringement Suit

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: [ MYL ]) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx® 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.  

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit [ www.mylan.com ]. For more information about generic drugs, please visit [ www.ChoosingGenerics.com ].  

SOURCE Mylan Inc.

[ Back to top ]

RELATED LINKS
[ http://www.mylan.com ]


Publication Contributing Sources